seolounge
CNN Business – Boston, June 21, 2025 — SyntecBio inc , an emerging leader in artificial intelligence-powered biotechnology, has announced the launch of the AI & Digital Biotech Conference 2025, to be held on September 18, 2025, at the Boston Convention & Exhibition Center. With over 500 expected attendees from more than 30 countries, the one-day event aims to accelerate the fusion of machine learning and molecular science in modern healthcare.
Industry insiders are calling it one of the most significant AI-in-biotech events of the year, bringing together research scientists, pharmaceutical executives, regulatory leaders, and startup founders under one roof—or virtual ceiling.
AI in Biotech: From Vision to Validation
“Biotech is entering its AI renaissance,” said Dr. Alicia Moreno, CEO of SyntecBio. “This conference is designed to not only showcase innovation, but to foster strategic collaboration that brings AI breakthroughs from research labs into real-world clinical impact.”
The event will showcase cutting-edge technologies across four tracks:
- AI in Drug Discovery – Covering AI/ML platforms for compound screening, target prediction, and trial optimization.
- Synthetic Biology 2.0 – Exploring automation, strain engineering, and digital twins for biology.
- Digital Therapeutics – Highlighting FDA-cleared AI treatments and real-time patient data integration.
- Venture & Startup Spotlight – Featuring 15+ pitch sessions from early-stage biotech companies harnessing AI.
Conference Highlights
- Keynote Address: “Can AI End the Antibiotic Resistance Crisis?” by Dr. Michael Tanaka, Chief Scientific Officer of Novartica Pharmaceuticals.
- Panel Discussion: “Ethics of AI in Biotech”, moderated by Dr. Elaine Wu of the U.S. FDA, with panelists from the World Bioethics Institute, SyntecBio, and MIT Media Lab.
- Live Technology Demo: A real-time walkthrough of SyntecBio’s NEURADapt™ platform, which uses AI to design personalized cancer therapies based on genomic data.
SyntecBio’s Vision
The Boston-based company has made waves with its NEURADapt™ system, currently in use at two major U.S. cancer centers. According to internal reports, the platform has reduced preclinical drug development time by up to 40%.
“From early discovery to late-stage trials, our goal is to use AI not just for speed, but for smarter, safer science,” said Dr. Lena Hughes, SyntecBio’s Chief Technology Officer.
Logistics & Registration
- Date: Thursday, September 18, 2025
- Time: 9:00 AM – 6:00 PM EST
- Location: Boston Convention & Exhibition Center, 415 Summer Street, Boston, MA
- Virtual Access: Available globally with live streaming and interactive Q&A
- website : https://syntecbiofuel.com/
About SyntecBio
Founded in 2019, SyntecBio is a biotechnology firm specializing in AI-accelerated solutions for drug discovery, diagnostics, and precision therapeutics. Based in Boston, Massachusetts, the company partners with research hospitals and pharma giants to reduce development time and cost while enhancing accuracy.